Literature DB >> 21908503

Bladder cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

J Bellmunt1, A Orsola, T Wiegel, M Guix, M De Santis, V Kataja.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21908503     DOI： 10.1093/annonc/mdr376

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  18 in total

1.  Hypofractionated palliative radiotherapy for bladder cancer.

Authors:  Piet Dirix; Sofie Vingerhoedt; Steven Joniau; Ben Van Cleynenbreugel; Karin Haustermans
Journal:  Support Care Cancer       Date:  2015-05-16       Impact factor: 3.603

Review 2.  [When should the primary tumor of metastatic bladder or prostate cancer be treated using a nonsurgical regimen?]

Authors:  D Bottke; C Bolenz; S Ott; A Cebulla; T Wiegel
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

3.  Implementation and assessment of a fast-track programme to improve communication between primary and specialized care in patients with suspected cancer: how to shorten time between initial symptoms of cancer, diagnosis and initiation of treatment.

Authors:  M T Martínez; I González; N Tarazona; S Roselló; R Saiz; A Sanmartín; Á Martínez-Agulló; A Caballero; P Mas; J Franco; J Martínez-Jabaloyas; J García-Callejo; V Martín; J Navarro; A Teruel; A Lluch; I Chirivella
Journal:  Clin Transl Oncol       Date:  2014-08-07       Impact factor: 3.405

Review 4.  Management of Clinically Regional Node-Positive Urothelial Carcinoma of the Bladder.

Authors:  Chanan Reitblat; Joaquim Bellmunt; Boris Gershman
Journal:  Curr Oncol Rep       Date:  2021-02-09       Impact factor: 5.075

5.  Diagnosis of bladder cancer from the voided urine specimens using multi-target fluorescence in situ hybridization.

Authors:  Zunfu Ke; Yuanhua Lai; Xudong Ma; Shuhua Lil; Wenhua Huang
Journal:  Oncol Lett       Date:  2013-12-09       Impact factor: 2.967

6.  Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment.

Authors:  Jung Hyun Lee; Sung Gu Kang; Seung Tae Kim; Seok Ho Kang; In Keun Choi; Young Je Park; Sang Chul Oh; Deuk Jae Sung; Jae Hong Seo; Jun Cheon; Sang Won Shin; Yeul Hong Kim; Jun Suk Kim; Kyong Hwa Park
Journal:  Cancer Res Treat       Date:  2014-04-22       Impact factor: 4.679

7.  Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice.

Authors:  Daniel Castellano; Javier Puente; Guillermo de Velasco; Isabel Chirivella; Pilar López-Criado; Nicolás Mohedano; Ovidio Fernández; Icíar García-Carbonero; María Belén González; Enrique Grande
Journal:  BMC Cancer       Date:  2014-10-24       Impact factor: 4.430

8.  CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers.

Authors:  Huang Chen; Yu Liu; Chuanzhen Cao; Hao Xi; Wenting Chen; Wei Zheng; Xin Dong; Shan Zheng; Lin Li; Jianhui Ma; Yanning Gao; Jianzhong Shou
Journal:  Ann Transl Med       Date:  2021-05

9.  Urine telomerase for diagnosis and surveillance of bladder cancer.

Authors:  Angela Lamarca; Jorge Barriuso
Journal:  Adv Urol       Date:  2012-07-25

10.  Inhibition of autophagy potentiates atorvastatin-induced apoptotic cell death in human bladder cancer cells in vitro.

Authors:  Minyong Kang; Chang Wook Jeong; Ja Hyeon Ku; Choel Kwak; Hyeon Hoe Kim
Journal:  Int J Mol Sci       Date:  2014-05-08       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.